![Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update | npj Primary Care Respiratory Medicine Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update | npj Primary Care Respiratory Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41533-023-00330-1/MediaObjects/41533_2023_330_Fig2_HTML.png)
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update | npj Primary Care Respiratory Medicine
![Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update | npj Primary Care Respiratory Medicine Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update | npj Primary Care Respiratory Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41533-023-00330-1/MediaObjects/41533_2023_330_Fig3_HTML.png)
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update | npj Primary Care Respiratory Medicine
![Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder](https://mms.businesswire.com/media/20200921005170/en/819864/4/Interactive_Media_Placeholder_webready.jpg)
Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder
![Bronchodilator reversibility in asthma and COPD: findings from three large population studies | European Respiratory Society Bronchodilator reversibility in asthma and COPD: findings from three large population studies | European Respiratory Society](https://erj.ersjournals.com/content/erj/54/3/1900561/F2.large.jpg)
Bronchodilator reversibility in asthma and COPD: findings from three large population studies | European Respiratory Society
![Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update | npj Primary Care Respiratory Medicine Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update | npj Primary Care Respiratory Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41533-023-00330-1/MediaObjects/41533_2023_330_Fig6_HTML.png)
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update | npj Primary Care Respiratory Medicine
![Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update | npj Primary Care Respiratory Medicine Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update | npj Primary Care Respiratory Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41533-023-00330-1/MediaObjects/41533_2023_330_Fig4_HTML.png)